Enovis

ENOV

Market cap $1.73B

Enovis Corporation ( ENOV ) UBS Global Healthcare Conference 2025 November 10, 2025 2:45 PM EST Company Participants Damien McDonald - CEO & Director Phillip Berry - Senior VP & CFO Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right. Good afternoon, everyone.

Enovis Corporation ( ENOV ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Kyle Rose - Vice President of Investor Relations Damien McDonald - CEO & Director Phillip Berry - Senior VP & CFO Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Young Li - Jefferies LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Michael Matson - Needham & Company, LLC, Research Division Russell Yuen - William Blair & Company L.L.C., Research Division Danielle Antalffy - UBS Investment Bank, Research Division Dane Reinhardt - Robert W.

Enovis (ENOV) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.73 per share a year ago.

Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" section of Enovis' website at www.enovis.com . Additionally, the company also announced it will participate in the following investor conferences:

Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners, a multi-family asset management firm based in Chicago, for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million, and up to $15 million payable in the future upon the achievement of certain milestones.

Wilmington, DE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will now present at the Baird 2025 Global Healthcare Conference at 2:35 p.m. ET on Wednesday, September 10th, 2025.

The consensus price target hints at a 69.9% upside potential for Enovis (ENOV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Enovis remains out of favor despite solid results, but I still see potential for mid-single-digit revenue growth and low double-digit FCF margins long-term. The Recon business is performing well, gaining share in extremities, while P&R remains a slow-growth drag on overall performance and valuation. Tariff risks are manageable, but I'm unimpressed by the new CEO's lack of ortho experience.

The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.